TD Cowen raises Helius Medical Technologies price target to $6.20 as neurostimulation trial timing shifts and commercialization expectations remain under review

Helius Medical Technologies and TD Cowen are the apparent focus, with a stock price target reportedly raised to $6.20 in connection with trial timing and updated commercial expectations. The available URL structure points to a market news item rather than a psychedelic-specific source, and no clearly central psychedelic substance is identifiable from the exact link alone. Trial timing likely refers to the scheduling of a clinical or regulatory milestone that could affect investor expectations, valuation, and near-term execution. Without reliable access to the exact page content, details such as the therapeutic area, named executives, analyst rationale, and publication date remain uncertain, so classification is limited to broad business and industry context.